血清钙磷水平在唑来膦酸治疗过程中对乳腺癌骨转移病灶进展的诊断价值

徐蓓; 李倩; 周宇红; 刘天舒

doi:10.12025/j.issn.1008-6358.2020.20201019

血清钙磷水平在唑来膦酸治疗过程中对乳腺癌骨转移病灶进展的诊断价值

Diagnostic value of serum calcium and phosphorus levels in progression of bone metastasis of breast cancer during zoledronic acid therapy

摘要

摘要:
目的探讨接受唑来膦酸治疗下，血清钙磷水平变化的程度对乳腺癌骨转移进展的诊断价值。
方法收集2014年1月至2019年12月于复旦大学附属中山医院肿瘤内科接受唑来膦酸治疗的明确存在骨转移的复发转移性乳腺癌患者。筛选治疗过程中出现骨转移病灶进展的患者临床资料，采用单样本t检验评估血钙和血磷水平随时间的改变程度。
结果本研究共纳入我院收治的女性乳腺癌患者42例，平均年龄（53.67±11.07）岁。患者血钙和血磷水平在骨转移进展前1个月、2个月、3个月和6个月时，相较基线状态时的变化的程度均无统计学差异（P均>0.05）。
结论对于接受唑来膦酸治疗过程中的乳腺癌骨转移患者，血清钙磷水平的变化可能不能较影像学检查更早反映骨转移病灶进展的情况。

Abstract:
Objective To investigate the diagnostic value of serum calcium and phosphorus levels in the progression of bone metastasis of breast cancer during zoledronic acid therapy.
Methods The clinical features were collected from breast cancer patients who underwent zoledronic acid therapy and had bone metastasis in Zhongshan Hospital, Fudan University between January 2014 and December 2019. A single sample t-test was performed to analyze the changes in serum calcium and phosphorus levels over time.
Results Forty-two female patients with bone metastasis breast cancer were included, with a mean age of (53.67 ±11.07) years. During zoledronic acid treatment, the serum calcium and phosphorus levels 1 month, 2 months, 3 months and 6 months before progression of bone metastasis were not statistically different from those at the baseline (P>0.05).
Conclusions For breast cancer patients with bone metastasis progression, changes in serum calcium and phosphorus levels may not reflect the progression of bone metastases earlier than imaging examination.

HTML全文

参考文献(12)

施引文献

资源附件(0)